The Role of Renal Dysfunction in Chronic Heart Failure of Rheumatic Etiology and Therapeutic Possibilities
Downloads
Chronic heart failure (CHF) is one of the most common clinical syndromes among the global population and is considered a severe complication of cardiovascular diseases, as well as one of the leading causes of mortality and disability [23]. CHF has been diagnosed in 1.0–2.6% of the population in Europe, 2.2% in the United States, and 7% in the Russian Federation, with this prevalence increasing with age [12, 15]. Rheumatic heart defects play a significant role in the etiology of CHF, which is associated with their high prevalence, including in Uzbekistan [13, 25]. In CHF, renal dysfunction develops in the form of cardiorenal syndrome, which intensifies the interconnection between the heart and kidneys [25]. In recent years, growing attention has been paid to the cardio- and nephroprotective effects of empagliflozin, a drug from the group of selective sodium-glucose cotransporter 2 (SGLT2) inhibitors [19]. The measures adopted in Uzbekistan to improve healthcare quality and prevent non-communicable diseases further underscore the relevance of this study [PD-60, 2022]. This article examines renal dysfunction and the effects of empagliflozin in CHF that has developed on the background of rheumatic heart defects.
1. Andrew A. House, Christoph Wanner, Mark J. Sarnak, Ileana L. Pina, Christopher W. McIntyre, Paul Komenda, Bertram L. Kasiske, Anita Deswal, Christopher R. deFilippi, John G.F. Cleland, Stefan D. Anker, Charles A. Herzog, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayerand Peter A. McCullough; for Conference Participants. KDIGO execut i v e conclusions - Kidney International (2019) 95, 1304–1317
2. Bock JS, Gottlieb SS. Cardiorenal syndrome. Circulation. 2010;121:2592–2600
3. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi GL, Tavazzi L, Maggioni AP, Latini R. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail 2013;1:417–424. 5.
4. Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR, Fried L, Newman AB, Kritchevsky SB, Sarnak MJ, Shlipak MG, Health ABC Study. Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis 2014;64:49–56. 6.
5. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010;96:1297–1302
6. Di Lullo L, House A, Gorini A, et al. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015;20:259–272
7. Ebner N., Jankowska E.A., Ponikowski P., Lainscak M., Elsner S., Sliziuk V. et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int. J. Cardiol. 2016; 6–12. DOI: 10.1016/j.ijcard.2015.11.178;
8. Femke Waanders M.D. et al. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial // Am. J. Kidney Dis. — 2009. — Vol. 53,№ 1. — Р. 16-25.
9. Geng
